Riitta Lassila, MD, PhD

Professor of Coagulation Medicine
Helsinki University Hospital, Coagulation Disorders Unit, Department of Haematology, Comprehensive Cancer Centre, and Research Program Unit in System Oncology, University of Helsinki, Helsinki, Finland

Riitta Lassila, MD, PhD, Professor of Coagulation Medicine at Univeristy of Helsinki, Faculty of Medicine, European Haemophilia and Allied Disorders (EAHAD) Comprehensive Care Centre, Department of Haematology and Comprehensive Cancer Centre in Helsinki University Hospital, Helsinki, Finland.
Prof. Lassila is engaged with clinical and translational studies, including outcome markers and new treatment modalities of Coagulation disorders. She is the former chair of the Nordic Haemophilia Council, the Finnish Society of Angiology and the current Chair of the Finnish Blood diseases research foundation. She has served as a secretary of the executive board of European Association of Haemophilia and Allied Disorders, EAHAD. Riitta Lassila has consulted EMA, FiMEA, Finnish Medicolegal affairs in Valvira, Institute of Health and Welfare in Finland (THL) and WHO. She is the member of EHA scientific program committee and of ISTH in 2024/2025. She has served as an associate editor in Thrombosis Research and as a member of editorial board in Haemophilia for several years,. Currently she is the associate editor for Journal of Thrombosis Haemostasis. Prof. Lassila has authored over 300 articles in scientific peer-review journals.

Presentation(s):

• SOA 04.4 - Uri Seligsohn State-of-the-Art Lecture: Rare/Unclassified Bleeding Disorders (Treatment, Diagnosis, Mechanism)

  Sunday, July 10, 2022
  8:00 AM – 9:15 AM

• OC 18.5 - APAC Treatment Limits Collar-induced Carotid Atherosclerotic Plaque Development in ApoE-/- Mice

  Sunday, July 10, 2022
  11:45 AM – 12:00 PM

• PB0739 - Interaction of Antiplatelet and Anticoagulant APAC with Complement Proteins Attenuates Complement Activation via C1q and Factor H

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1160 - WAPPS-Hemo as a tool for optimizing prophylaxis with extended half-life FIX in patients with severe or moderate hemophilia B

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM